An endemic areas of the biggest and smallest incidence rates for all cancer within Silesia Voivodeship
More details
Hide details
Zakład Epidemiologii i Śląski Rejestr Nowotworów Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie, Oddział w Gliwicach. Kierownik: Prof. dr hab. n. med. Brunon Zemła
Brunon Zemła   

Zakład Epidemiologii i Śląski Rejestr Nowotworów Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie Oddział w Gliwicach ul. Wybrzeże Armii Krajowej 45 44-101 Gliwice tel./fax +48 32 278 12 03 tel. kom. +48 601 068 763
Med Srod. 2012;15(3):35–45
The Silesia Cancer Register conducts systematic monitoring of the cancer incidence since 60-years XX c. within Silesia voivodeship. The Register encompasses the area that is inhabited about 4.8 mln inhabitants, according to the Main Bureau of Statistics. Amount of the persons suffering for cancer constantly increasing, although unequally by smaller administrative units, i.e 36 districts. Therefore necessity looking for really endemic area, especially with the biggest and smallest cancer incidence rates.

Material and Methods:
Using the M. Segi’s and M. Kurihara’s procedure in the R. Doll’s modification the average incidence rates (partial, crude and standardized by the “age-world population structure”) – were calculated. The analysis was based on the 183.396 cases of persons (males, females) that were suffered on this area in the years 1999–2009.

In the year 1999–2009 in Silesia Voivodeship, 94.001 cases of all cancer (i.e 51.3 % from total) were diagnosed among males, and 89.395 cases (i.e 48.7%) among females. Age-adjusted incidence rates varied from minimum 227.0 to maximum 327.0/100 thousand (average for whole areas – 272.4/100 thousand) among males and females. The distribution of age-standardized cancer incidence rates (in periods: 1999–2009, 1999–2002 and 2006– 2009) for all sites by both sexes is very unequal. The rates of incidence were used in the chorological type of analyses (a looking for of endemic areas especially with the biggest incidence). There endemic areas were described (vide fig 1D and 2D). The most frequent and long-lasting suffering males and females in the following counties: będziński, bielski, cieszyński, mikołowski and towns: Bielsko-Biała, Chorzów, Dąbrowa Górnicza, Gliwice, Jaworzno, Jastrzębie-Zdrój, Katowice, Tychy, Żory.

This analysis is a based to organize of diverse mainly prevention activities, i.e anti-cancer education, screenings, etc.

Ferleay J., Shin H.R., Bray F. i wsp.: Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int. J. Cancer 2010; 127/12: 2893-2917.
Parkin D.M., Bray F., Ferlay J. i wsp.: Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74-108.
Ries L.A.G., Eisner M.P., Kosary C.L. i wsp. (eds): SEER cancer statistics review, 1975–2001. Bethesda, MD : Nat. Cancer Inst. 2004.
Sant M., Aareleid T., Berrino F. i wsp.: Eurocare Working Group. EUROCARE – 3: survival of cancer patients diagnosed 1990–94 – results and commentary. Ann. Oncol. 2003; 14: 61–118.
Preston S.H., Ho J.Y.: Low life expectancy in the United States: is the health care system of fault? PSC Working Paper Series. PSC Univ. Pen. 09 - 03 2009; 1–46.
Verdecchia A., Francisi S., Brenner H. i wsp.: Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE – 4 data. Lancet Oncol. 2007; 8: 784–796.
Wojciechowska U., Didkowska J., Zatoński W.: Nowotwory złośliwe w Polsce – wskaźniki 5-letnich przeżyć według województw. Krajowy Rejestr Nowotworów Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie w Warszawie. Warszawa 2010; 5–54.
Nowotwory złośliwe w Polsce w 1990 roku. Pod red. W. Zatońskiego i J. Tyczyńskiego. Z-d Organizacji Walki z Rakiem i Epidemiologii Nowotworów Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie w Warszawie. Warszawa 1993; 1–76.
Wojciechowska U., Didkowska J., Zatoński W.: Nowotwory złośliwe w Polsce w 2008 roku. Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie w Warszawie. Warszawa 2010; 3–116.
Bates M.N., Rey O.A., Biggs M.L. i wsp.: Case – control study of bladder cancer and exposure to arsenic in Argentina. Am. J. Epidemiol. 2004; 159: 381-389.
Celik I., Gallicchio L., Boydet K. i wsp.: Arsenic in drinking water and lung cancer: a systematic review. Environ. Res. 2008; 108: 48–55.
Chen Ch.L., Yichiou H., Ihsu L. i wsp.: Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. Environ. Res. 2010; 110: 455–462.
Hsueh Y., M., Cheng G., S., Wu M., M. i wsp.: Multiple risk factors associated with arsenic – induced skin cancer: effects of chronic liver disease and malnutritional status. Br. J. Cancer 1995; 71: 109–114.
Boffetta P., Nyberg F.: Contribution of environmental factors to cancer risk. Br. Med. Bull. 2003; 68: 71–94.
Brima E.I., Haris P.I., Jenkins R.O. i wsp.: Understanding arsenic metabolism through a comparative study of arsenic level in the urine, hair and fingernails of healthy volunteers from three unexposed ethnic group in the United Kingdom. Toxicol. Appl. Pharmacol. 2006; 216: 112–130.
Hata A., Endo Y., Nakajima Y. i wsp.: HPLCICP – MS speciation analysis of arsenic in urine of Japanese subjects without occupational exposure. J. Occup. Health 2007; 49: 217–223.
Hughes M.F.: Biomarkers of exposure: a case study with inorganic arsenic. Environ. Health Perspect. 2006; 114: 1790–1796.
Stavrides J.C.: Lung carcinogenesis. Pitoval role of metals in tobacco smoke. Free Radic. Biol. Med. 2006; 41: 1017–1030.
Sorahan T.J., Harrington J.M.: Lung cancer in Yorkshire chrome platters, 1972–97. Occup. Environ. Med. 2000; 57: 385–389.
Luippold R.S., Mundt K.A., Panko J. i wsp. Lung cancer mortality among chromate production workers. Occup. Environ. Med. 2003; 60: 451–457. Wesseling C., Pukkala E., Neuvonen K. i wsp.: Cancer of the brain and nervous system and occupational exposures.
in Finnish women. J. Occup. Environ. Med. 2002; 44(7): 663–668.
Cole P., Rodu B.: Epidemiologic studies of chrome and cancer mortality: a series of meta – analyses. Red. Toxicol. Pharmacol. 2005; 43: 225–231.
International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC, Lyon 1993; 119–237.
Vinceti M., Venturelli M., Sighinolfi C. i wsp.: Case-control study of toenail cadmium and prostate cancer risk in Italy. Sci. Total Environ. 2007; 373: 77–81.
Hu J., Mao Y., White K.: Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup. Med. (London) 2002; 52: 157–164.
McElroy J.A., Shafer M.M., Trentham-Dietz A. i wsp.: Cadmium exposure and breast cancer risk. J. Natl Cancer Inst. 2006; 98: 869–872.
Strumylaite L., Bogusevicius A., Ryselis S. i wsp.: Association between cadmium and breast cancer. Medicina (Kaunas) 2008; 44: 415–420.
Waalkes M.: Cadmium carcinogenesis in review. J. Inorg. Biochem. 2000; 79: 241–244.
Pesch B., Haerting J., Ranft U. i wsp.: Occupational risk factors for renal cell carcinoma: agent specific results from a case-control study in Germany. Int. J. Epidemiol. 2000;29: 1014–1024.
Gać P., Pawlas K.: Stężenia selenu we krwi w różnych populacjach osób zdrowych i chorych – przegląd piśmiennictwa z lat 2005–2010. Med. Środ. 2011; 14(1): 93–104.
Connelly-Frost A., Poole C., Satia J.A. i wsp.: Selenium,m folate and colon cancer. Nutr. Cancer 2009; 61: 165–178.
Ermakow V., Jovanovic L.: Selenium deficiency as a consequence of human activity and its correction. J. Geochem. Explor. 2010; 107: 193–199.
Charalabopoulos K., Kotsalos A., Batistatu A. i wsp.: Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA. Br. J. Cancer 2006; 95: 674–676.
Lopez-Fontana C.M., Perez-Elizalde R.F., Vanrell M.C. i wsp.: Relation between selenium plasma levels and different prostatic pathologies. Actas Urol. Esp. 2010; 34: 625–629.
Alatise O.I., Schrauzer G.N.: Lead exposure: a contributing cause of the current breast cancer epidemic in Nigerian women. Biol. Trace Elem. Res. 2010; 136: 127–139.
Chan J.M., Oh W.K., Xie W. i wsp.: Plasma selenium, manganese superoxide dismutase, and intermediate – or high – risk prostate cancer. J. Chin. Oncol. 2009; 27: 3577– 3583.
Yuan J.M., Gao Y.T., Ong C.N. i wsp.: Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J. Natl Cancer Inst. 2006; 98: 482–490.
Wojcieszyńska D., Guzik U., Hupert-Kocurek K. i wsp.: Biochemiczne i fizjologiczne skutki oddziaływania związków fenolowych na organizm człowieka. Med. Środ. 2010; 14(1): 105–111.
Michałowicz J., Duda W.: Phenols-sources and toxicity. Polish J. Environ. Stud. 2007; 16: 347–362.
Omieljaniuk N., Moniuszko-Jakoniuk J.: Fenol. Post. Hig. Med. Dośw. 1987;41: 331–346.
Bechi N., Ietta F., Ramagnoli R. i wsp.: Environmental levels of para-nonylphenol are able to effect cytokine secretion in human placenta. Environ. Health Perspect. 2010; 118: 427–431.
Kogevinas M., Saracci R., Winkelmann R. i wsp.: Cancer incidence and mortality in women occupationally exposed to chlorophenoxy herbicides, chlorophenols, and dioxins. Cancer Causes Cont. 1993; 4: 547–553.
Zemła B.F.P., Kołosza Z., Banasik T.R.: Atlas zachorowalności i umieralności na nowotwory w obrębie województwa katowickiego w latach 1985–1993. Wyd. Zakład Epidemiologii Nowotworów Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie, Oddział w Gliwicach, Min. Zdr. i Opieki Społ. w Warszawie. Gliwice 1999;8–83.
Miettinen O.S., Nurminen M.: Comparative analysis of two rates. Stat. Med. 1985;4: 213–226.
Katz P., Babtista J., Azen S.P. i wsp.: Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics, 1978; 34: 469–474.